Pharmaceutical compositions with antiflaviviral activity

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

A method of inhibiting viral replication comprising:

• contacting one or more cells that have been infected with a virus with an effective amount of a compound, wherein the compound is
• or a pharmaceutically acceptable salt thereof and the virus is selected from the group consisting of Dengue virus serotype 1, Dengue virus serotype 2, Dengue virus serotype 3, Dengue virus serotype 4, yellow fever virus, West Nile virus, Zika virus, Japanese encephalitis virus, and any combination of two or more of the foregoing.

A method of inhibiting viral replication comprising:

• administering to a human subject an effective amount of a compound, wherein the compound is
• or a pharmaceutically acceptable salt thereof and the virus is selected from the group consisting of Dengue virus serotype 1, Dengue virus serotype 2, Dengue virus serotype 3, Dengue virus serotype 4, yellow fever virus, West Nile virus, Zika virus, Japanese encephalitis virus, and any combination of two or more of the foregoing.